- Home
- TR vs NAMS Comparison
TR vs NAMS Comparison
Compare TR & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TR | NAMS |
|---|---|---|
| Founded | 1896 | 2019 |
| Country | United States | Netherlands |
| Employees | 2100 | 100 |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TR | NAMS |
|---|---|---|
| Price | $41.98 | $28.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $46.75 |
| AVG Volume (30 Days) | 82.5K | ★ 861.9K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17.96 |
| Revenue Next Year | N/A | $540.65 |
| P/E Ratio | $32.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.59 | $16.79 |
| 52 Week High | $45.06 | $42.00 |
Technical Indicators
Market Signals| Indicator | TR | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 48.55 | 37.14 |
| Support Level | $41.55 | $23.48 |
| Resistance Level | $43.37 | $37.25 |
| Average True Range (ATR) | 1.25 | 1.76 |
| MACD | -0.12 | -0.65 |
| Stochastic Oscillator | 43.75 | 9.12 |
Price Performance
Historical ComparisonAbout TR Tootsie Roll Industries Inc.
Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.